Search
Sweden's Anocca is a TCR-T company with a unique approach that is going after unique targets, its first CTA will be filed soon
Co-Founder and CEO Reagan Jarvis describes Anocca's TCR mapping, discovery, and engineering approach, as well as why they have chosen...
Sep 20, 2024
Plymouth Meeting based Geneos Therapeutics is developing DNA-based personalized therapeutic cancer vaccines
Founder and CEO Niranjan Sardesai describes why is believes a personalized approach is important and how Geneos is working on the...
Sep 20, 2024
Houston/Philadelphia based ImmunoGenesis is trying to turn cold tumors hot with a PD‑L1/PD‑L2 dual‑specific inhibitor
CEO Jim Barlow explains the unmet need and how the company is going after cancers such as triple-negative breast, colorectal, and ovarian...
Sep 20, 2024
Pittsburgh based Neuro-Innovators is developing three drugs to improve neuroplasticity to enhance the effectiveness of rehab post-stroke
Co-Founder and CEO Howison Schroeder describes this unmet need for chronic stroke patients and how Neuro-Innovators is working on a...
Sep 20, 2024
With expertise in delivering drugs to the liver, Medivir recently had data at ESMO for its lead liver cancer drug, fostrox
CEO Jens Lindberg describes the recent ESMO data and the next steps for this program. And he covers two others that are available for...
Sep 19, 2024
Vicore Pharma's CEO describes the rationale for using angiotensin II type 2 receptor agonists in IPF
Ahmed Mousa describes what excited him to join the company from the U.S. one year ago, the unmet need that still exists in this large...
Sep 19, 2024
Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics
CEO David Veitch describes the news and expands on the success of Basilea's business model.
Sep 19, 2024
BioInvent's CEO highlights TNFR2 data recently presented at ESMO, and more in the company's pipeline
Martin Welschof describes this target that BioInvent is at the forefront of, including single agent data they have seen, and covers other...
Sep 19, 2024
The co-founder of Stockholm's Stratipath talks digital pathology and what it was like to spin out of the prestigious Karolinska Institute
Johan Hartman introduces us to the Karolinska Institute, where his company has benefitted from its Innovations arm, and describes how...
Sep 18, 2024
Oxford BioTherapeutics' OGAP platform, a cancer specific membrane protein library, has enabled the company to find cancer targets for its own pipeline and partners alike
CEO Christian Rohlff describes the expertise the company has build and describes pipeline assets, including partnerships with Boehringer,...
Sep 18, 2024
Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond
New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how he thinks Nucleome is in a unique...
Sep 17, 2024
Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating
CEO Iain Kilty describes the keys to intervening in cell metabolism, and discusses pipeline assets such as a PKM2 for atopic dermatitis...
Sep 17, 2024
Since 1986, Madrid's PharmaMar has been searching the world's oceans for new cancer medicines - it has already led to three approved drugs
Managing Director Luis Mora walks us through the company's development process, from divers in the ocean, to sample testing, and...
Sep 17, 2024
Getting a general overview of protein splicing at Barcelona's SpliceBio
Co-Founder & CEO Miquel Vila-Perelló describes the rationale for protein splicing , how it works, and he shares an overview of the...
Sep 16, 2024
From Biocom California's Women's Health Conference: The Co-Founder and CEO of AccendoWave describes the importance of understanding women's pain data
Martha Lawrence's company has databases on women in pain and maternal health in pain. She explains how customers such as the government...
Sep 16, 2024
Veracyte's CEO talks about ESMO data from its prostate cancer diagnostic that could change how metastatic prostate cancer is treated
Marc Stapley explains how the company's Decipher Prostate Test, already successful commercially in localized prostate cancer, could help...
Sep 16, 2024
In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor
CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly...
Sep 14, 2024
Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress
He discusses data from the Nectin-4 targeting zelenectide pevedotin program, Nectin-4 + CD137, and EphA2.
Sep 14, 2024
The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens
John Lewis describes the limitations of AAV and LNPs, and how the Entos construct is meant overcome them. Plus, a summary of the...
Sep 13, 2024
Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development
Danny Bar-Zohar describes Merck KGaA's three pillars of healthcare research: oncology, neurology, and immunology. Plus, the advantages of...
Sep 12, 2024
.png){kind=logo}
